Guangdong Province Institute of Gastroenterology

Qingxin(Cindy) Liu(Assistant Professor)

01/01/28-05/01/03 B. Sc San Francisco State University, San Francisco, CA Cell and Molecular Biology

08/08/05-13/05/17 Ph.D Drexel University College of Medicine, Philadelphia Pharmacology and Physiology

Research Experiences：

13/09/09 – 16/04/10 Postdocteral Fellow, Department of Systems Biology, The University of

Texas MD Anderson Cancer Center, Houston, USA

Projects: 1. Revealed the synergism of mTOR and PARP inhibitors in TNBC and underlying mechanism

2. Validated a 10-gene signature that predicts homologous recombination repair defects in various cancer cell lines, and investigated the clinical applications of this signature in predicting sensitivity to PARP inhibitor treatment in cancer patients

16/08/10 - Current : Assistant Professor, Research Institute of Gastroenterology, Sun Yat-sen University, Guangzhou, Guangdong, China

1、Mo W*, Liu Q*, Dai H, Lin CJ, Peng Y, Liang Y, Meric-Bernstam F, Mills GB, Li K, and Lin SY. mTOR inhibitors suppress homologous recombination repair and synergize with PARP inhibitors via regulating SUV39H1 in BRCA-proficient triple- negative breast cancer. Clin Cancer Res. 2016 Apr 1;22(7):1699-712)
2、Liu Q, Russell MR, Shahriari K, Jernigan D, Lioni Mi, Garcia, F and Fatatis, A. Interleukin-1 promotes skeletal colonization and progression of metastatic prostate cancer cells with neuroendocrine features. Cancer Research 73, 3297 (2013)
3、Russell MR, Liu Q, and Fatatis A. Targeting the alpha receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clinical Cancer Research 16, 5002-5010 (2010)
4、Russell MR, Liu Q, Lei H, Kazlauskas A, and Fatatis A. The alpha receptor for platelet derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Cancer Research 70, 4195-4203 (2010)

1. metabolism reprograming in colorectal cancer progression

2. tumor microenvironment in colorectal cancer progression

3. the roles of DNA damage repair mechanism dysregulation in colorectal cancer drug resistance